How should I review and manage potential drug interactions before initiating or changing therapy?

Managing Drug Interactions Before Initiating or Changing Therapy

Use a systematic risk-stratification approach: check all medications using crediblemeds.org or interaction checker software, prioritize alternatives over monitoring when adding interacting drugs, and perform targeted ECG/lab monitoring only for high-risk combinations rather than routine screening for all potential interactions. 1

Systematic Pre-Prescription Review Process

Step 1: Screen All Medications for Interactions

• Use validated interaction checker tools (crediblemeds.org with smartphone app, Lexicomp®, or institutional software) to identify potential drug-drug interactions before prescribing 1, 2
• Review ALL medications including:
  • Prescription drugs
  • Over-the-counter preparations
  • Herbal/complementary medicines
  • Vitamins and supplements 3

Step 2: Risk Stratification Framework

Apply clinical judgment based on three key factors:

1. The specific drug and dose being initiated
2. Patient-specific risk factors (age, sex, renal/hepatic function, cardiac disease, electrolyte status)
3. Coexistence of other interacting medications or conditions 1

Step 3: Choose Your Management Strategy

Prioritize in this order:

1. FIRST CHOICE: Select a non-interacting alternative - This is preferable to monitoring 1

   • Example: Choose penicillin/cephalosporin instead of quinolone antibiotic when patient already takes QT-prolonging drug 1
   • Among macrolides: azithromycin has lowest risk vs. erythromycin (highest) 1
   • Among SSRIs: sertraline/paroxetine safer than citalopram/escitalopram 1

2. SECOND CHOICE: Temporarily discontinue the interacting medication if clinically appropriate

   • Example: Stop statin for 8-12 weeks during hepatitis C treatment 4
   • Discontinue simvastatin when starting pazopanib 5

3. THIRD CHOICE: Dose adjustment with monitoring when alternatives unavailable 5, 4

4. LAST RESORT: Enhanced monitoring only for unavoidable combinations 5

High-Risk Situations Requiring Pre-Treatment ECG/Labs

Obtain baseline ECG before initiating QT-prolonging drugs when: 1

• Patient already receiving another QT-prolonging medication
• Electrolyte disturbance present (especially with diuretic use)
• Initiating high-risk agents (methadone, sotalol, class I/III antiarrhythmics)
• Borderline QTc prolongation already exists
• Female sex, elderly, or structural heart disease present

DO NOT routinely obtain ECG for low-risk scenarios (e.g., healthy person starting sertraline) 1

Critical thresholds: Risk increases when QTc >500 ms or drug increases QTc by >60-70 ms 1

Specific High-Risk Drug Classes Requiring Vigilance

Remember the "Anti's" for QT Prolongation: 1

• Antibiotics (macrolides, fluoroquinolones)
• Antifungals (azoles)
• Antiarrhythmics
• Antipsychotics/Antidepressants
• Antiemetics
• Analgesics (methadone, triptans)

CYP3A4/P-gp Interactions: 5, 6, 7, 8

• Contraindicated combinations: Strong CYP3A4 inhibitors/inducers with DOACs, tyrosine kinase inhibitors, certain statins
• Avoid: Simvastatin/lovastatin with protease inhibitors or azole antifungals 6, 9
• Class I/III antiarrhythmics with protease inhibitors (risk of torsades de pointes) 6

Anticoagulant Combinations: 7

• Limit triple therapy (anticoagulant + dual antiplatelet) to ≤30 days maximum
• Add proton pump inhibitor prophylactically
• Prefer DOACs over warfarin when combining with antiplatelets

Ongoing Monitoring Strategy

When patient takes QTc-prolonging medication: 1

• Monitor electrolytes and renal function regularly
• Especially critical if taking diuretics or has renal impairment
• Watch for hypokalemia/hypomagnesemia with sotalol + diuretic combinations

For high-risk drug pairs that cannot be avoided: 5

• Consider therapeutic drug monitoring (TDM) for narrow therapeutic index drugs
• Perform ECG after each dose change for methadone and similar high-risk agents 1

Monitor for hepatotoxicity when combining: 5

• Tyrosine kinase inhibitors with statins (pazopanib + simvastatin)
• Check transaminases at weeks 4,8,12 4

Common Pitfalls to Avoid

1. Prescribing cascade: New symptoms in elderly patients should be considered potential adverse drug reactions BEFORE adding another medication 3

2. Assuming all drugs in a class are equivalent: Intraclass differences are substantial (e.g., erythromycin vs. azithromycin) 1

3. Relying solely on automated alerts: Only ~10% of potential interactions are clinically significant; clinical judgment essential 10, 11

4. Forgetting renal/hepatic dose adjustments: Many interacting drugs accumulate with organ dysfunction 1, 4

5. Inadequate patient medication history: Must ask about ALL products including herbals, OTC, supplements 5, 3

Special Populations

Elderly/Polypharmacy patients: 3, 10

• Risk increases exponentially: 10.9% with 2-4 drugs → 80.8% with ≥10 drugs
• More vulnerable to pharmacodynamic interactions
• Higher baseline risk for QT prolongation (especially women)

Renal impairment: 1, 7

• Exacerbates DOAC drug interactions more than warfarin interactions
• Requires dose reduction for quinolones, azole antifungals, sotalol

Women: 1

• Higher risk for drug-induced QT prolongation and torsades de pointes
• Counsel about contraception needs with ribavirin (6 months post-treatment) 4